On #WorldBrainTumorDay, @SirenBio stands with every patient and family living with a brain tumor. Brain tumors like high-grade glioma are among the hardest cancers to treat, and that urgency drives everything we do. We're advancing SRN-101, our #AAV Immuno #GeneTherapy for high-grade glioma, to the clinic for patients who need it most. Let's sound the alarm against #cancer!

As #GrayMay comes to a close, we're reminded of why we show up every day at @SirenBio. High-grade gliomas are among the hardest cancers to treat. Survival is still measured in months for most patients, and meaningful new options have been slow to arrive. There are now two open INDs for SRN-101, our lead asset in recurrent high-grade glioma, and every step forward is motivated by the patients, families, and caregivers facing this disease head-on. Let's sound the alarm against cancer. #GrayMay #BrainTumorAwarenessMonth #GeneTherapy #Cancer

Our team had a wonderful time connecting with collaborators and fellow #AAV #GeneTherapy experts last week at #ASGCT2026! Highlights were talking great science at our annual Siren happy hour and presenting some of our large animal and CMC data. Missed our poster and talk? Check them out on our website: sirenbiotechnology.com/publi…

@SirenBio is headed to #ASGCT2026 next week! Find us at the events below to learn more about our path to the clinic with #SRN101, our lead AAV immuno #genetherapy for #cancer. See you in Boston! Happy Hour RSVP: luma.com/kl56nvvt

BIG moment for @SirenBio 🚨 We’re thrilled to share that our first peer-reviewed manuscript is now published in @CellPressNews Molecular Therapy Oncology - and we’re heading to @ASGCTherapy 2026 with even more data to share! This publication showcases the foundation of our Universal AAV Immuno-Gene Therapy platform, including groundbreaking preclinical data in high-grade glioma, one of the toughest cancers with the greatest unmet need. Huge thanks to our team and collaborators for supporting this work! 👉 Read the full press release here: sirenbiotechnology.com/siren… 👉 Access the open access manuscript here: cell.com/molecular-therapy-f… Want more, like our IND large animal data?! Come find us at #ASGCT2026! #AAV #GeneTherapy #Immunotherapy #Oncology #Publication

Join @SirenBio's CEO @Nicole_Paulk and other industry leaders at the NORD Scientific Symposium next week! We’ll be sharing ways to bring community members in as company stakeholders through community fundraising. Register here: nordscience.org/

Thrilled to see @SirenBio SAB member Beverly Davidson recognized with the Outstanding Achievement Award by @ASGCTherapy! A well-deserved honor celebrating her pioneering work and lasting impact on the field 🌟

Big news for SRN-101 🚀 The FDA has cleared a second IND to launch a Phase 1 trial with SRN-101 in recurrent high-grade glioma. This investigator-initiated study, led by Dr. Nicholas Butowski at @UCSF, marks an exciting step forward in expanding clinical evaluation of SRN-101. We’re so proud to support the UCSF team as they advance this important work for patients in need! Learn more: sirenbiotechnology.com/Siren…

On the heels of IND clearance for SRN-101, we are thrilled to announce another major milestone at @SirenBio! 🚀 The FDA has granted #FastTrack Designation to SRN-101, our lead Universal #AAV Immuno-Gene Therapy candidate for recurrent high-grade glioma 🧠 Fast Track status reinforces the urgency and potential impact of bringing this first-of-its-kind therapy to patients. Momentum is building and we’re just getting started! 💥

The @SirenBio team is heading to Phacilitate #ATW26 next week. Our Founder & CEO, @Nicole_Paulk, and our SVP of Vector Development Nathalie Clement look forward to meeting with partners, peers, and fellow leaders pushing the field forward. If you’ll be in San Diego, we’d love to see you!

A big day of celebration here at @SirenBio! 🎉 We’re thrilled to share that the FDA has cleared our first IND for SRN-101, enabling our Phase I/II trial of what we believe is the first #AAV #GeneTherapy for any #cancer clinically. This milestone marks a major step forward in bringing SRN-101 to patients with recurrent high-grade glioma. Huge congratulations to our incredible team, advisors, and partners who helped make this moment possible!

It’s a busy start to 2026 at @SirenBio! We’re excited to be out in full force at #JPM2026, #ATW2026, and #BiocomGPIC. Come meet with us at: 📍 JPM Jan 12-15 | San Francisco, CA 📍 Advanced Therapies Feb 9-12 | San Diego, CA 📍 Biocom Feb 24-26 | La Jolla, CA If you’ll be there too, let’s connect!

Happy holidays from the @SirenBio team!🎄Our key moments were submitting our first IND to the FDA (today!) and closing our first-ever community investment round. But these can’t overshadow all the other accomplishments our team had in 2025. In all, we counted: ⚡ 8 new cancer indications tested 💸 1,529 new investors ✍️ First IND filed 🧠 3 new SAB members 🧪 10 formal assay qualifications 🏅 3 big awards received 🧬 100 new constructs screened 💪 1 cancer diagnosis AND recovery! 💼 7 conferences attended 🐣 1 new baby 📆 50 weekly syncs and 26 lab meetings 🥹 1 proud team with ♾️ accomplishments…make that ♾️ 1! 💛 Stay tuned for our 2026 tally…

🚀 Hey #founders and builders! Thinking about opening your own community investment round? We just dropped the full recording of our webinar where the @SirenBio team walks through how we approached - and successfully ran - our own community round. It’s not legal or financial advice, just an honest look at what worked for us (and what we learned along the way). If you’re a founder curious about bringing your supporters in as investors, this is a great place to start. Featuring: @Nicole_Paulk and Akela Kuwahara from @SirenBio Nina Ekmescic from Capital Department Jonny Price from @Wefunder 🎥 Watch the full video here: youtu.be/kn4gEIIS_sc #StartupFunding #CommunityRound #BiotechStartups #Founders

Only a few hours left, and that’s it! ⏳ The momentum in these final hours has been incredible. We’re closing in on $4M raised from over 1,500 investors, and we couldn’t be more proud of what this community has built. Here’s why investors are excited about Siren: 🧬Universal AAV gene therapy for cancer 💸$28M raised from top-tier VCs including Founders Fund and Lux Capital 🏆Named 2025 Start-Up of the Year at Phacilitate Advanced Therapies Week 🔬550 animals treated with curative preclinical data 🧪Clinical trials targeted for 2026 🎓Team from Stanford, UCSF, Duke, Mount Sinai, and Roche 🎖️First patent family awarded 👑Called “perhaps the most de-risked pharma startup” by Kingscrowd 🌍Tackling a $3.2B global market for brain tumor therapeutics 🎙️Featured at SXSW 2025 We opened this round to give more people a seat at the table in building the future of cancer care and we’ve been blown away by your belief, support, and boldness. ❤️ 🚨Join us or increase your stake before our round closes for good → wefunder.com/sirenbiotechnol…

🚨We’re almost at the finish line – Siren’s community investment round closes TONIGHT This is your final chance to invest in the company developing a universal AAV immuno-gene therapy for cancer. 💸 $28M raised from top VCs including Founders Fund, Lux Capital & more 🧬 $3.8M raised from 1,500 community investors (and counting!) 🏆 2025 Start-Up of the Year at Phacilitate Advanced Therapies Week 🧠 Game-changing universal AAV gene therapy 🔬 550 animals treated with curative preclinical data 🧪 Targeting clinical trials in 2026, a critical step toward FDA approval 🎓 Powerhouse team from Stanford, UCSF, Duke, Mount Sinai, and Roche 🌍 $3.2B global market for brain tumor therapeutics Let’s bring a radically new kind of cancer treatment into the world. 🎯Invest or increase your investment before 11:59pm EST: 👉wefunder.com/sirenbiotechnol… Here we go!

We just wrapped our Virtual Closing Celebration and we’re still feeling the energy and deep gratitude from this incredible community. 🥂 1,450 #investors have already joined our mission to change the future of #cancer care and we can’t keep count fast enough! If you missed the event, the replay is now live: 🎥Watch the replay → youtube.com/watch?v=QWJUEqBd… 📅Book a call with our Founder & CEO → calendly.com/npaulk/15-min-m… Our community round closes in just a few days, and we don’t plan to open another. If you’ve been thinking about investing, increasing your stake, or sharing this with someone who should be part of it, act now. This has been one of the most meaningful chapters in Siren Biotechnology's journey. Let’s finish strong! 🚀 🔗 Invest now at wefunder.com/sirenbiotechnol….

Join the @SirenBio team for our final community investor webinar TODAY! 🗓 Wednesday, October 15 🕚 11:30am PT / 2:30pm ET 🎟️ RSVP here: luma.com/dlyq5t6j Can't make the webinar but still want to chat about investing before the round closes this week? Book a time to speak with our Founder and CEO, @Nicole_Paulk here! calendly.com/npaulk/15-min-m…